Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 805 results for "alexion pharmaceuticals"

New Strong Sell Stocks for May 26th - Tale of the Tape

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Alexion Pharmaceuticals, Inc. ( ALXN ) Genesee & Wyoming Inc ( GWR ) Packaging Corp Of America (PKG ) TreeHouse Foods Inc. (THS) Gamco Investors Inc (GBL) ... Yahoo! Finance, 21 hours ago

9 images for alexion pharmaceuticals

American Banking News, 1 day ago
Jutia Group, 1 month ago
Waterbury Republican American, 3 weeks ago
Social Dashboard, 4 weeks ago, 4 weeks ago, 1 month ago, 1 month ago
Hartford Business Journal, 1 month ago
I Stock Analyst, 1 month ago

Potential Alexion Pharmaceuticals (ALXN) Trade Targets 4.14% Return

( via COMTEX) -- Alexion Pharmaceuticals Inc ( ALXN ) presents a trading opportunity that offers a 4.14% return in just 53 days. A covered call on Alexion Pharmaceuticals at the $170.00 level expiring on Jul. '15 ...
 TradingCharts.com21 hours ago Alexion Pharmaceuticals (ALXN) Showing Support Near $159.05  Individual.com6 days ago Alexion Pharmaceuticals (ALXN) Trading Near $156.42 Support Level  Individual.com1 week ago Alexion Pharmaceuticals (ALXN) Down In Pre-Market Trading  TheStreet.com2 weeks ago

Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.00%

Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $167.31 to a high of $172.65. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $169.26 on volume of 2.6 million ...
 Individual.com4 days ago Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 1.62% Rise  Individual.com1 week ago Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 1.04% Yesterday  Individual.com1 week ago


Document Format Files Seq Description Document Type Size 1 SCHEDULE TO t1501057-scto.htm SC TO-T 65127 2 EXHIBIT (A)(5)(F) t1501057-sctoexa5f.htm EX-99.(A)(5)(F) 15565 3 GRAPHIC t1501057_ex-a5f.jpg GRAPHIC 5279996 Complete submission text file ...
 SEC4 days ago ALEXION PHARMACEUTICALS INC (0000899866) (Filed by)  SEC Filings2 weeks ago

Alexion announces encouraging data from Phase II kidney transplant study

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, has announced encouraging preliminary one-year data from a single-arm Phase II study of eculizumab, or Soliris, in the prevention of acute antibody-mediated rejection, or AMR, in sensitized ...
 Individual.com5 days ago

Too soon for pay rises, claims former Ibec head

Clamour for reversal of cuts is opportunistic and not well thought through Julie ONeill of Alexion Pharmaceuticals: I don't think we are at a stage in the economic recovery where businesses in any sense can afford to give those level of pay cuts ...
 Irish Times1 week ago

Alexion Pharmaceuticals: A Focus on Treating Rare Disorders

The Ins and Outs of the SynagevaAlexion Merger ( Continued from Prior Part ) Alexion: Abiopharmaceutical company focused on rare diseases Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company focused on treatments for rare diseases.
 Yahoo! Finance1 week ago

Alexion Pharmaceuticals Pays up to Get Synageva Biopharma

Alexion Moves to Boost Treatment Portfolio with Synageva Merger spread analysis To perform merger arbitrage, the investor will generally buy the stock of the company being acquired and wait for the deal to close. When the deal is completed, the ...
 Yahoo! Finance2 weeks ago

Alexion reports lower Q1 net income, provides outlook for 2015

Alexion Pharmaceuticals, Inc. has reported that net income for the first quarter ended March 31, 2015 was $91.32 million, or $0.45 per diluted share, compared to $159.35 million, or $0.79 per diluted share, for the same quarter ended March 31, 2014.
 Individual.com2 weeks ago

Alexion Pharmaceuticals to acquire Synageva BioPharma

Deals Alexion Pharmaceuticals have agreed to acquire Synageva BioPharma for a total consideration of $8.3 billion. Value: $8.3 billion Announced: May 06 2015 Parties involved Legal advisers Alexion Pharmaceuticals ...
 International Law Office2 weeks ago Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating...  Pharmacy Choice1 week ago Pharma firm Alexion to buy peer Synageva  Business Times Singapore2 weeks ago Alexion to buy Synageva for jaw-dropping $8.4 billion  Pharma Field2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - alexion pharmaceuticals
Get updated on latest news & your favorite topics right in your inbox!
More     Less